5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow astegolimab: new trials by email Literature Review of astegolimab trials Research Report on astegolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Astegolimab, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Genentech, Inc. | 1334 | 2021-10-05 | 2026-10-16 |
| A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia MSTT1041A, MSTT1041A-matched Placebo, UTTR1147A - COVID-19 Pneumonia | Phase 2 | Completed | Genentech, Inc. | 396 | 2020-06-02 | 2022-01-10 |
| A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis MSTT1041A, Placebo - Atopic Dermatitis | Phase 2 | Completed | Genentech, Inc. | 65 | 2019-02-06 | 2023-05-06 |
| Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) MSTT1041A, Placebo - COPD Exacerbation | Phase 2 | Completed | University of Leicester | 81 | 2018-10-11 | 2022-06-21 |
| A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma MSTT1041A, Placebo - Asthma | Phase 2 | Completed | Hoffmann-La Roche | 517 | 2016-09-20 | 2022-12-28 |
Pulmonary Disease, Chronic Obstructive (2) · Asthma (1) · Dermatitis, Atopic (1)
Genentech, Inc. (3) · Hoffmann-La Roche (1) · University of Leicester (1)
United States (4) · Germany (3) · Poland (3) · Argentina (2) · Belgium (2) · Bulgaria (2) · Canada (2) · Czechia (2) · Mexico (2) · New Zealand (2) · Peru (2) · Romania (2) · South Africa (2) · South Korea (2) · Spain (2)
Christopher Brightling, Prof (1)
PMID 33872652, PMID 35339234, PMID 36253275, PMID 36519984, PMID 42148875, PMID 42150581
2018 (2), 2016 (1)